Show simple item record

dc.contributor.authorSade, Juan P.
dc.contributor.authorMonteiro, Fernando.
dc.contributor.authorSchutz, Fabio.
dc.contributor.authorEt al.
dc.date.accessioned2023-06-23T15:01:38Z
dc.date.available2023-06-23T15:01:38Z
dc.date.issued2021-04
dc.identifier.citationJCO Glob Oncol . 2021 Apr;7:538-544.es
dc.identifier.issn2687-8941
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/2200
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162965/pdf/go-7-go.20.00508.pdf
dc.descriptionDisponible en: https://ascopubs.org/doi/10.1200/GO.20.00508?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmedes
dc.description.abstractAbstract Purpose: To present a summary of the treatment and follow-up recommendations for the biochemical recurrence in castration-sensitive prostate cancer (PCa) acquired through a questionnaire administered to 99 PCa experts from developing countries during the Prostate Cancer Consensus Conference for Developing Countries. Methods: A total of 27 questions were identified as related to this topic from more than 300 questions. The clinician's responses were tallied and presented in a percentage format. Topics included the use of imaging for staging biochemical recurrence, treatment recommendations for three different clinical scenarios, the field of radiation recommended, and follow-up. Each question had 5-7 relevant response options, including "abstain" and/or "unqualified to answer," and investigated not only recommendations but also if a limitation in resources would change the recommendation. Results: For most questions, a clear majority (> 50%) of clinicians agreed on a recommended treatment for imaging, treatment scenarios, and follow-up, although only a few topics reached a consensus > 75%. Limited resources did affect several areas of treatment, although in many cases, they reinforced more stringent criteria for treatment such as prostate-specific antigen values > 0.2 ng/mL and STAMPEDE inclusion criteria as a basis for recommending treatment. Conclusion: A majority of clinicians working in developing countries with limited resources use similar cutoff points and selection criteria to manage patients treated for biochemically recurrent castration-sensitive PCa.es
dc.language.isoenes
dc.publisherAmerican Society of Clinical Oncologyes
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectProstate Cancer.es
dc.subjectCastration prostate cancer.es
dc.subjectBiochemical Recurrence.es
dc.titleConsensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countrieses
dc.typeArticlees


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional